Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):924–929. doi: 10.1054/bjoc.2001.2004

Cell surface antigens in renal tumour cells: detection by immunoluminescence and enzymatic analysis

F Laube 1, B Göhring 2, H Sann 1, I Willhardt 1
PMCID: PMC2375078  PMID: 11556847

Abstract

Two renal cell carcinoma cell lines (49RC 43STR and 75RC 2STR) were characterized by detection of the cell surface proteins: CD44(var), intercellular adhesion molecule-1 (ICAM-1), urokinase-type plasminogen activator (uPA) and its receptor and aminopeptidase N (APN). To detect their localization the immunoluminescent technique was used. In addition, the enzyme activity of uPA and APN was investigated in cell suspensions as well as in monolayers. The latter procedure was more advantageous since the additional use of HPLC permits a single registration of the fluorescent hydrolysis-product AMC (7-amino-4-methylcoumarin) without interference by cellular autofluorescence or non-reacted fluorescent substrate. Unlike 75RC 2STR, the cell line 49RC 43STR expressed high levels of uPA and APN. Contrary to that the cell line 75RC 2STR expressed high levels of ICAM-1 and CD44(v6), whereas 49RC 43STR showed a low level of ICAM-1 and no distinct light signal with anti-CD44(v6). The uPA activity was measured directly as well as indirectly (via plasmin) with the substrate Z-Gly-Gly-Arg-AMC. Both activator and plasmin activity were inhibited by D-Val-Phe-Lys-CMK and phenylmethylsulfonyl fluoride. The anti-catalytic antibody to uPA and that to uPA receptor were found to be inhibiting the uPA activity in a concentration-dependent manner. APN activity was assayed using alanine-p-nitroanilide. Peptidase activity was effectively inhibited by 1,10-phenanthroline and partly inhibited by ethylenediamine-tetraacetic acid. © 2001 Cancer Research Campaignhttp://www.bjcancer.com

Keywords: renal cell carcinoma, CD44(var), ICAM-1, urokinase-type plasminogen activator, aminopeptidase N, immunoluminescence

Full Text

The Full Text of this article is available as a PDF (2.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andreasen P. A., Kjøller L., Christensen L., Duffy M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997 Jul 3;72(1):1–22. doi: 10.1002/(sici)1097-0215(19970703)72:1<1::aid-ijc1>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Cubellis M. V., Wun T. C., Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J. 1990 Apr;9(4):1079–1085. doi: 10.1002/j.1460-2075.1990.tb08213.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gilcrease M. Z., Truong L., Brown R. W. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol. 1996 Dec;27(12):1355–1360. doi: 10.1016/s0046-8177(96)90350-0. [DOI] [PubMed] [Google Scholar]
  4. Goebeler M., Kaufmann D., Bröcker E. B., Klein C. E. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci. 1996 Jul;109(Pt 7):1957–1964. doi: 10.1242/jcs.109.7.1957. [DOI] [PubMed] [Google Scholar]
  5. Gohji K., Nakajima M., Boyd D., Dinney C. P., Bucana C. D., Kitazana S., Kamidono S., Fidler I. J. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol. 1997 Dec;151(6):1655–1661. [PMC free article] [PubMed] [Google Scholar]
  6. Göhring B., Holzhausen H. J., Meye A., Heynemann H., Rebmann U., Langner J., Riemann D. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med. 1998 Oct;2(4):409–414. doi: 10.3892/ijmm.2.4.409. [DOI] [PubMed] [Google Scholar]
  7. Hansen A. B., Lillevang S. T., Andersen C. B. Stimulation of intercellular adhesion molecule-1 (ICAM-1) antigen expression and shedding by interferon-gamma and phorbol ester in human renal carcinoma cell cultures: relation to peripheral blood mononuclear cell adhesion. Urol Res. 1994;22(2):85–91. doi: 10.1007/BF00310997. [DOI] [PubMed] [Google Scholar]
  8. Hara I., Miyake H., Yamanaka K., Hara S., Arakawa S., Kamidono S. Expression of CD44 adhesion molecules in nonpapillary renal cell carcinoma and normal kidneys. Urology. 1999 Sep;54(3):562–566. doi: 10.1016/s0090-4295(99)00177-6. [DOI] [PubMed] [Google Scholar]
  9. Heider K. H., Ratschek M., Zatloukal K., Adolf G. R. Expression of CD44 isoforms in human renal cell carcinomas. Virchows Arch. 1996 Jul;428(4-5):267–273. doi: 10.1007/BF00196700. [DOI] [PubMed] [Google Scholar]
  10. Høyer-Hansen G., Ploug M., Behrendt N., Rønne E., Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem. 1997 Jan 15;243(1-2):21–26. doi: 10.1111/j.1432-1033.1997.0021a.x. [DOI] [PubMed] [Google Scholar]
  11. Kirchheimer J. C., Pflüger H., Hienert G., Binder B. R. Increased urokinase activity to antigen ratio in human renal-cell carcinoma. Int J Cancer. 1985 Jun 15;35(6):737–741. doi: 10.1002/ijc.2910350607. [DOI] [PubMed] [Google Scholar]
  12. Koelsch R., Gottwald S., Lasch J. Release of GPI-anchored membrane aminopeptidase P by enzymes and detergents has some peculiarities. Biochim Biophys Acta. 1994 Feb 23;1190(1):170–172. doi: 10.1016/0005-2736(94)90047-7. [DOI] [PubMed] [Google Scholar]
  13. Koga H., Naito S., Nakashima M., Hasegawa S., Watanabe T., Kumazawa J. A flow cytometric analysis of the expression of adhesion molecules on human renal cell carcinoma cells with different metastatic potentials. Eur Urol. 1997;31(1):86–91. doi: 10.1159/000474424. [DOI] [PubMed] [Google Scholar]
  14. Lischke A., Pagany M., Kammer W., Friedrich K. A chemiluminescence-based method for the detection and quantification of antigen-antibody interactions on the surface of eukaryotic cells. Anal Biochem. 1996 May 1;236(2):322–326. doi: 10.1006/abio.1996.0173. [DOI] [PubMed] [Google Scholar]
  15. Meissauer A., Kramer M. D., Schirrmacher V., Brunner G. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. Exp Cell Res. 1992 Apr;199(2):179–190. doi: 10.1016/0014-4827(92)90423-6. [DOI] [PubMed] [Google Scholar]
  16. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J. S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993 Sep 15;53(18):4143–4147. [PubMed] [Google Scholar]
  17. Nguyen D. H., Hussaini I. M., Gonias S. L. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J Biol Chem. 1998 Apr 3;273(14):8502–8507. doi: 10.1074/jbc.273.14.8502. [DOI] [PubMed] [Google Scholar]
  18. Paradis V., Ferlicot S., Ghannam E., Zeimoura L., Blanchet P., Eschwége P., Jardin A., Benoît G., Bedossa P. CD44 is an independent prognostic factor in conventional renal cell carcinomas. J Urol. 1999 Jun;161(6):1984–1987. [PubMed] [Google Scholar]
  19. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol. 1998 Nov;13(5):893–906. doi: 10.3892/ijo.13.5.893. [DOI] [PubMed] [Google Scholar]
  20. Riemann D., Kehlen A., Langner J. Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13. Clin Exp Immunol. 1995 May;100(2):277–283. doi: 10.1111/j.1365-2249.1995.tb03665.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Saiki I., Fujii H., Yoneda J., Abe F., Nakajima M., Tsuruo T., Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 1993 Apr 22;54(1):137–143. doi: 10.1002/ijc.2910540122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Stahl A., Mueller B. M. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer. 1997 Mar 28;71(1):116–122. doi: 10.1002/(sici)1097-0215(19970328)71:1<116::aid-ijc19>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  23. Stahl A., Mueller B. M. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J Cell Biol. 1995 Apr;129(2):335–344. doi: 10.1083/jcb.129.2.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Swiercz R., Wolfe J. D., Zaher A., Jankun J. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. Clin Cancer Res. 1998 Apr;4(4):869–877. [PubMed] [Google Scholar]
  25. Tanabe K., Campbell S. C., Alexander J. P., Steinbach F., Edinger M. G., Tubbs R. R., Novick A. C., Klein E. A. Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res. 1997;25(4):231–238. doi: 10.1007/BF00942091. [DOI] [PubMed] [Google Scholar]
  26. Wagner S. N., Atkinson M. J., Thanner S., Wagner C., Schmitt M., Wilhelm O., Rotter M., Höfler H. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma. Am J Pathol. 1995 Jul;147(1):183–192. [PMC free article] [PubMed] [Google Scholar]
  27. Yu Q., Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999 Jan 1;13(1):35–48. doi: 10.1101/gad.13.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Zimmerman M., Quigley J. P., Ashe B., Dorn C., Goldfarb R., Troll W. Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles. Proc Natl Acad Sci U S A. 1978 Feb;75(2):750–753. doi: 10.1073/pnas.75.2.750. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES